ReviewBMC gastroenterology2026
Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review.
Review in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTumor necrosis factor-α (TNF-α) inhibitors are first-line agents for steroid-refractory/resistant ulcerative colitis (UC), but their immunosuppressive effect elevates the risk of opportunistic infections, particularly tuberculosis (TB). Extrapulmonary TB such as hepatic and splenic TB is rare but prone to misdiagnosis. A 55-year-old male was diagnosed with UC in 2003, relieved by sulfasalazine and mesalazine for recurrence in 2021. In 2024, post-perianal abscess surgery, UC relapsed with positive cytomegalovirus (CMV), treated with glucocorticoids and ganciclovir. The patient subsequently developed glucocorticoid-dependent acute severe active UC, presenting with more than 10 bloody stools per day and a Mayo endoscopic score of 3 points. The patient failed to achieve symptom relief after one week of vedolizumab treatment, prompting an immediate adjustment of the therapeutic strategy, and infliximab was therefore initiated. After 6 infliximab doses, he developed fever. T-SPOT/PPD turned positive, with liver and spleen nodules. Biopsy showed epithelioid granulomatous inflammation, Xpert mycobacterium TB/RIF test was positive, leading to hepatic/splenic TB diagnosis. Quadruple anti-TB therapy was initiated. UC relapsed in December 2025, improved by guselkumab. Anti-tuberculosis treatment continues with planned re-evaluation after 1 year. DISCUSSION AND LITERATURE REVIEW: Hepatic/splenic TB lacks specificity, often mimicking drug-induced liver injury. Latest guidelines emphasize baseline TB screening (PPD + TSPOT.TB + chest CT) and 3-6 monthly surveillance during biologic use. Anti-TB drugs may exert synergistic anti-UC effects via cytokine inhibition. Extrapulmonary TB requires ≥ 12 months of anti-TB therapy.
conclusionClinicians should remain alert to hepatic/splenic TB in UC patients receiving biologic therapy, particularly those with sequential biologic exposure. Timely pathological and etiological diagnosis and anti-TB therapy improve prognosis, with strict TB surveillance crucial for early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.